| Entry |
|
|---|
| Name |
Tamoxifen citrate (JP18/USP);
Nolvadex (TN);
Soltamox (TN) |
|---|
| Product |
|
|---|
| Generic |
TAMOXIFEN CITRATE (A-S Medication Solutions), TAMOXIFEN CITRATE (A-S Medication Solutions), TAMOXIFEN CITRATE (Actavis Pharma), TAMOXIFEN CITRATE (Aurobindo Pharma Limited), TAMOXIFEN CITRATE (Bryant Ranch Prepack), TAMOXIFEN CITRATE (Bryant Ranch Prepack), TAMOXIFEN CITRATE (Bryant Ranch Prepack), TAMOXIFEN CITRATE (Golden State Medical Supply), TAMOXIFEN CITRATE (Mayne Pharma Commercial LLC), TAMOXIFEN CITRATE (McKesson Corporation dba SKY Packaging), TAMOXIFEN CITRATE (Mylan Pharmaceuticals), TAMOXIFEN CITRATE (NuCare Pharmaceuticals), TAMOXIFEN CITRATE (NuCare Pharmaceuticals), TAMOXIFEN CITRATE (Proficient Rx LP), TAMOXIFEN CITRATE (Zydus Lifesciences Limited), TAMOXIFEN CITRATE (Zydus Pharmaceuticals USA) |
|---|
| Formula |
C26H29NO. C6H8O7
|
|---|
| Exact mass |
563.2519
|
|---|
| Mol weight |
563.6381
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01585 Estrogen receptor antagonist
DG01620 Tamoxifene-type antineoplastic
Hormonal agent
DG01619 Estrogen receptor antagonist/modulator
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00734): | D00966<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Estrogen receptor agonist/antagonist |
|---|
| Disease |
Breast cancer (ER-positive) [DS: H00031] |
|---|
| Comment |
Active form of prodrug: Endoxifen [CPD: C16547]
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565], CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07226 | Progesterone, androgen and estrogen receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BA Anti-estrogens
L02BA01 Tamoxifen
D00966 Tamoxifen citrate (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antiestrogens/Modifiers
Tamoxifen
D00966 Tamoxifen citrate (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D00966 Tamoxifen citrate (JP18/USP)
Drug groups [BR:br08330]
Antineoplastic
DG01585 Estrogen receptor antagonist
DG01620 Tamoxifene-type antineoplastic
DG00734 Tamoxifen
D00966 Tamoxifen citrate
Hormonal agent
DG01619 Estrogen receptor antagonist/modulator
DG00734 Tamoxifen
D00966 Tamoxifen citrate
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00734 Tamoxifen
D00966 Tamoxifen citrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00734 Tamoxifen
D00966 Tamoxifen citrate
Drug classes [BR:br08332]
Antineoplastic
DG01585 Estrogen receptor antagonist
D00966 Tamoxifen citrate
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
Estrogen receptor
NR3A (ESR)
D00966 Tamoxifen citrate (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00966 Tamoxifen citrate
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00966
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D00966
Drug groups [BR:br08330]
Antineoplastic
DG01585 Estrogen receptor antagonist
DG01620 Tamoxifene-type antineoplastic
DG00734 Tamoxifen
Hormonal agent
DG01619 Estrogen receptor antagonist/modulator
DG00734 Tamoxifen
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00734 Tamoxifen
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00734 Tamoxifen
Prodrugs [br08324.html]
DG00734
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 41
1 C1d C 44.5200 -20.0900
2 C1b C 43.3300 -20.7900
3 C1b C 45.7100 -20.7900
4 C6a C 45.2200 -18.9000
5 O1a O 43.8200 -18.9000
6 C6a C 42.0700 -20.0900
7 C6a C 45.7100 -22.1900
8 O6a O 44.5200 -17.6400
9 O6a O 46.6200 -18.9000
10 O6a O 40.8800 -20.7900
11 O6a O 42.0700 -18.6900
12 O6a O 46.9700 -22.8900
13 O6a O 44.5200 -22.8900
14 C8x C 32.8300 -21.0700
15 C8y C 32.8300 -22.4700
16 C8x C 31.6400 -23.1700
17 C8x C 30.3800 -22.4700
18 C8y C 30.3800 -21.0700
19 C8x C 31.6400 -20.3700
20 C8x C 27.9300 -22.4700
21 C8y C 27.9300 -21.0700
22 C2c C 29.1900 -20.3700
23 C8x C 26.7400 -23.1700
24 C8x C 25.5500 -22.4700
25 C8x C 25.5500 -21.0700
26 C8x C 26.7400 -20.3700
27 C2c C 29.1900 -18.9700
28 C1b C 27.9300 -18.2700
29 C8y C 30.3800 -18.2700
30 O2a O 34.0200 -23.1700
31 C1b C 35.2100 -22.4700
32 C1b C 36.4000 -23.1700
33 C8x C 30.3800 -16.8700
34 C8x C 31.5700 -16.1700
35 C8x C 32.8300 -16.8700
36 C8x C 32.8300 -18.2700
37 C8x C 31.5700 -18.9700
38 N1c N 37.5900 -22.4700
39 C1a C 38.7800 -23.1700
40 C1a C 37.5900 -21.0700
41 C1a C 26.7400 -18.9700
BOND 42
1 1 2 1
2 1 3 1
3 1 4 1
4 1 5 1
5 2 6 1
6 3 7 1
7 4 8 1
8 4 9 2
9 6 10 1
10 6 11 2
11 7 12 1
12 7 13 2
13 14 15 2
14 15 16 1
15 16 17 2
16 17 18 1
17 18 19 2
18 14 19 1
19 20 21 1
20 21 22 1
21 18 22 1
22 20 23 2
23 23 24 1
24 24 25 2
25 25 26 1
26 21 26 2
27 22 27 2
28 27 28 1
29 27 29 1
30 15 30 1
31 30 31 1
32 31 32 1
33 29 33 2
34 33 34 1
35 34 35 2
36 35 36 1
37 36 37 2
38 29 37 1
39 32 38 1
40 38 39 1
41 38 40 1
42 28 41 1
|
|---|
